109451
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
IL-6 和 IL-10 表达水平与接受 R-CHOP 治疗的 B 细胞非霍奇金淋巴瘤患者预后的关系
Authors Dong Q, Lin W, Yu S, Qin Y, Jia C, Wang N, Xiu W, Shan W, Dong M, Liu D
Received 3 April 2025
Accepted for publication 5 September 2025
Published 25 October 2025 Volume 2025:18 Pages 14791—14804
DOI https://doi.org/10.2147/JIR.S532323
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Felix Marsh-Wakefield
Quan Dong,1,* Wenxin Lin,1,* Saihui Yu,1 Yuxin Qin,1 Chuiming Jia,2 Na Wang,3 Wei Xiu,4 Weiqi Shan,5 Mei Dong,1,* Duo Liu1,*
1Department of Pharmacy, Harbin Medical University Cancer Hospital, Harbin, 150086, People’s Republic of China; 2Hematology Department, Harbin Medical University Cancer Hospital, Harbin, 150086, People’s Republic of China; 3Department of Science and Education, Heilongjiang Provincial Hospital, Harbin, 150036, People’s Republic of China; 4Department of Pharmacy, Heilongjiang Forest Industry General Hospital, Harbin, 150040, People’s Republic of China; 5Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, 150086, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Duo Liu, Department of Pharmacy, Harbin Medical University Cancer Hospital, Harbin, 150086, People’s Republic of China, Email liuduo95@126.com Mei Dong, Department of Pharmacy, Harbin Medical University Cancer Hospital, Harbin, 150086, People’s Republic of China, Email 13804567370@163.com
Purpose: To explore the relationship between the expression of IL-6 and IL-10 in the blood of B-cell non-Hodgkin lymphoma (B-NHL) patients and their survival time and adverse reactions.
Methods: The study collected and analyzed blood samples from 488 patients with B-NHL treated with rituximab (94 serum samples, 394 plasma samples) as well as plasma samples from 202 healthy subjects, along with relevant clinical information. Expression levels of IL-6 and IL-10 in the blood were measured using enzyme-linked immunosorbent assay (ELISA).
Results: The expression of IL-6 in the plasma of B-NHL patients was significantly higher than those in healthy subjects (P < 0.001). Patients with low IL-6 expression (serum) had longer Event Free Survival (EFS) compared to those with high IL-6 expression (P = 0.011). Patients with low IL-10 expression (plasma) had longer Progression Free Survival (PFS) (P = 0.009) and EFS (P = 0.027) compared to those with high IL-10 expression. For patients with collected serum samples, non-GCB have shorter PFS (P = 0.027) and EFS (P = 0.03) than GCB patients. The COX proportional hazards regression model results suggest that elevated plasma IL-10 levels (P = 0.008) and advanced stage (P < 0.001) are risk factors for PFS in B-NHL patients.
Conclusion: The expression of IL-6 and IL-10 in the blood can serve as important biomarkers for predicting the prognosis of rituximab in patients with B-NHL.
Keywords: IL-6, IL-10, rituximab, B-NHL, prognosis
1Department of Pharmacy, Harbin Medical University Cancer Hospital, Harbin, 150086, People’s Republic of China; 2Hematology Department, Harbin Medical University Cancer Hospital, Harbin, 150086, People’s Republic of China; 3Department of Science and Education, Heilongjiang Provincial Hospital, Harbin, 150036, People’s Republic of China; 4Department of Pharmacy, Heilongjiang Forest Industry General Hospital, Harbin, 150040, People’s Republic of China; 5Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, 150086, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Duo Liu, Department of Pharmacy, Harbin Medical University Cancer Hospital, Harbin, 150086, People’s Republic of China, Email liuduo95@126.com Mei Dong, Department of Pharmacy, Harbin Medical University Cancer Hospital, Harbin, 150086, People’s Republic of China, Email 13804567370@163.com
Purpose: To explore the relationship between the expression of IL-6 and IL-10 in the blood of B-cell non-Hodgkin lymphoma (B-NHL) patients and their survival time and adverse reactions.
Methods: The study collected and analyzed blood samples from 488 patients with B-NHL treated with rituximab (94 serum samples, 394 plasma samples) as well as plasma samples from 202 healthy subjects, along with relevant clinical information. Expression levels of IL-6 and IL-10 in the blood were measured using enzyme-linked immunosorbent assay (ELISA).
Results: The expression of IL-6 in the plasma of B-NHL patients was significantly higher than those in healthy subjects (P < 0.001). Patients with low IL-6 expression (serum) had longer Event Free Survival (EFS) compared to those with high IL-6 expression (P = 0.011). Patients with low IL-10 expression (plasma) had longer Progression Free Survival (PFS) (P = 0.009) and EFS (P = 0.027) compared to those with high IL-10 expression. For patients with collected serum samples, non-GCB have shorter PFS (P = 0.027) and EFS (P = 0.03) than GCB patients. The COX proportional hazards regression model results suggest that elevated plasma IL-10 levels (P = 0.008) and advanced stage (P < 0.001) are risk factors for PFS in B-NHL patients.
Conclusion: The expression of IL-6 and IL-10 in the blood can serve as important biomarkers for predicting the prognosis of rituximab in patients with B-NHL.
Keywords: IL-6, IL-10, rituximab, B-NHL, prognosis